Determination of desmoglein 1 and 3 antibody levels by ELISA in patients with pemphigus after treatment with rituximab

Determination of desmoglein 1 and 3 antibody levels by ELISA in patients with pemphigus after treatment with rituximab as adjuvant and comparison with other adjuvants

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220117053747N1

Enrollment

Registered

2022-01-27

Start date

2022-03-21

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus. Pemphigus

Interventions

Intervention 1: Intervention group: Patients will receive prednisone 5 mg tablet daily (Iran Hormone Pharmaceutical Company, Iran) and rituximab 500 mg (Actovorco Pharmaceutical Company, Iran) as adju

Eligibility

Sex/Gender

All

Age

16 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with pemphigus vulgaris Patients with pemphigus follicia Active pemphigus disease Patients being treated for pemphigus Patients resistant to previous treatments Patients resistant to previous treatments

Exclusion criteria

Exclusion criteria: Having active infections Cardiac arrhythmia or cardiac conduction disorders Ejection fraction below 40% Evidence of other autoimmune diseases History of receiving ritoximab in the past Pregnancy and breastfeeding Patients with a history of allergies and anaphylactic shock

Design outcomes

Primary

Measure	Time frame
Pemphigus disease severity. Timepoint: Will be evaluated 1, 3 and 6 months after the intervention. Method of measurement: Pemphigus Disease Area Index.;Desmoglein 1 and 3 antibody level. Timepoint: Will be evaluated before intervention and 1, 3 and 6 months after the intervention. Method of measurement: Elisa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArmaghan Ghareh Aghaji Zare

Tabriz University of Medical Sciences

ghareaghajia@tbzmed.ac.ir+98 41 3549 8236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026